Recent News

• 11.26.2025 - Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference
• 11.03.2025 - Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results
• 10.21.2025 - Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025
• 10.14.2025 - Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis
• 09.15.2025 - Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
• 09.15.2025 - Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
• 09.15.2025 - Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
• 09.02.2025 - Krystal Biotech to Present at Cantor Global Healthcare Conference 2025
• 09.02.2025 - Krystal Biotech to Present at Cantor Global Healthcare Conference 2025
• 09.02.2025 - Krystal Biotech to Present at Cantor Global Healthcare Conference 2025

Recent Filings

• 11.03.2025 - 8-K Current report
• 11.03.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.03.2025 - EX-99.1 EX-99.1
• 10.22.2025 - 8-K Current report